<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21538">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01694212</url>
  </required_header>
  <id_info>
    <org_study_id>MZJ-2106</org_study_id>
    <nct_id>NCT01694212</nct_id>
  </id_info>
  <brief_title>Preoperative Topic Diclofenac as a Prevention of Postoperative Macular Edema in Patients With Diabetic Retinopathy</brief_title>
  <official_title>Effect of Perioperative Topical Diclofenac on Intraocular Inflammation After Cataract Surgery and the Incidence of Postoperative Macular Edema in Patients With Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye Clinic Medic Zuljan Jukic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Hospital Center, Split</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zagreb</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eye Clinic Medic Zuljan Jukic</source>
  <oversight_info>
    <authority>Croatia: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes has many negative effects on patients' general health. Among many other
      consequences it speeds up the cataract formation and that is why diabetic patients need
      cataract surgery very often. The known side effect of cataract surgery even in otherwise
      healthy patients is postoperative edema of the back of the eye (what causes decrease of
      vision), which has greater incidence especially in patients who have diabetic eye problems.
      The cause of that might be the intraocular inflammation which was previously demonstrated to
      be significantly more prominent in patients with untreated diabetic eye problems. Therefore
      we will examine if the 7 day use of anti-inflammatory eye drops prior to the cataract
      surgery prevent the formation of the edema of the back of the eye.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change of Central Macular Thickness</measure>
    <time_frame>-7, 0, 1, 7, 30, 90 days after the cataract surger</time_frame>
    <safety_issue>No</safety_issue>
    <description>The central macular thickness will be measured with OCT machine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression of diabetic retinopathy</measure>
    <time_frame>-7 and 90 days after cataract surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>The grade of diabetic retinopathy will be assessed on fundus photographies according to ETDRS criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-12 concentration</measure>
    <time_frame>immediately before cataract surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>The IL-12 concentration will be measured in the sample of humour aqueous taken at the beginning of cataract surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Macular Edema</condition>
  <condition>Cataract</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Diclofenac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with diabetic retinopathy having preoperative treatment with diclofenac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group having placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perioperative Diclofenac eye-drops administration</intervention_name>
    <arm_group_label>Diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of nonproliferative diabetic retinopathy

          -  presence of the cataract (LOCS 2-3)

        Exclusion Criteria:

          -  other chronic or acute eye diseases

          -  hypersensitivity to any component of the diclofenac eye-drops patients on oral
             anticoagulant therapy

          -  allergy to salycilates
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ljubo Znaor, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Hospital Center, Split</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Poliklinika Medic Zuljan JukiÄ‡</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 26, 2012</lastchanged_date>
  <firstreceived_date>September 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Hospital Center, Split</investigator_affiliation>
    <investigator_full_name>Ljubo Znaor</investigator_full_name>
    <investigator_title>Ophthalmologist</investigator_title>
  </responsible_party>
  <keyword>Macular edema</keyword>
  <keyword>Cataract</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>Anti-inflammatory agents,Non-steroidal</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
